Once-daily versus twice-daily lamivudine, in combination with Zidovudine and Efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial

DeJesus, Edwin; McCarty, Debra; Farthing, Charles F.; Shortino, Denise D.; Grinsztejn, Beatriz; Thomas, Deborah A.; Schrader, Shannon R.; Castillo, Steve A.; Sension, Michael G.; Gough, Kevin; Madison, Sam J..
Artículo en Inglés | ARCA | ID: arc-31318

Documentos relacionados

  1. [Chronic hepatitis B virus infection: current and future treatment strategies].
  2. [HIV infection: relevant pediatric aspects].
  3. [Contact Investigation in Active Tuberculosis and Management of Latent TB Infection: 5-year Analysis at a German City Health Authority].
  4. [Multisystemic inflammatory syndrome in children after severe acute respiratory syndrome coronavirus 2 infection: a clinical analysis of four cases].
  5. [Chronic hepatitis C virus infection: clinical picture and treatment possibilities].
  6. [Chronic Tropheryma whipplei infection: an important differential diagnosis of refractory polyarthritis].
  7. [Drug therapy interventions for acute SARS-CoV-2 infection: who, when, and what?]
  8. [Clostridium difficile Infection: Epidemiology, Clinical Presentation, Therapy and Prevention].
  9. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.
  10. [Hemophagocytic syndrome due to lung infection: a case report].